Investing.com - Aytu BioScience reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Aytu BioScience announced earnings per share of $-0.490 on revenue of $27.45M. Analysts polled by Investing.com anticipated EPS of $-0.370 on revenue of $25.5M.
Aytu BioScience shares are down 53.76% from the beginning of the year and are trading at $0.190 , down-from-52-week-high.
Aytu BioScience follows other major Healthcare sector earnings this month
Aytu BioScience's report follows an earnings beat by Merck ADR on Friday, September 9, 2022, who reported EPS of $0.5392 on revenue of $5.69B, compared to forecasts EPS of $0.5165 on revenue of $5.57B.
Veeva Systems A had beat expectations on Wednesday, August 31, 2022 with second quarter EPS of $1.03 on revenue of $534.22M, compared to forecast for EPS of $1.01 on revenue of $530.71M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar